<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650102</url>
  </required_header>
  <id_info>
    <org_study_id>81571319</org_study_id>
    <nct_id>NCT02650102</nct_id>
  </id_info>
  <brief_title>The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment</brief_title>
  <official_title>The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases,&#xD;
      including schizophrenia (SZ). The previous work has indicated a strong genetic association&#xD;
      between the miRNA-30e precursor (pre-miR-30e) and the risk of SZ. However, to date, few&#xD;
      reports have focused on the expression level of the miR-30 family (miR-30s) and its networks&#xD;
      of co-regulation in SZ, even in response to antipsychotic treatment. Given this, the&#xD;
      investigator first constructed a hybrid miRNA-TF (transcription factor)-gene-PPI&#xD;
      (protein-protein interactions) network focusing on miR-30s by bioinformatics technology. The&#xD;
      investigator then selected several candidate miR-30s and key regulators for further&#xD;
      validation. These candidates were then quantified by real-time quantitative PCR (qRT-PCR) in&#xD;
      an independent cohort of 200 healthy controls and 200 drug-free SZ patients, among which were&#xD;
      followed up by 12-week antipsychotic treatment. Furthermore, the investigator evaluated the&#xD;
      correlation between the change in gene expression and the improvement of symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is one of the most serious mental disorder，which is characterized by high&#xD;
      prevalence rate ,high recurrence rate, could increase patients' disability and burden of&#xD;
      disease. But the pathological mechanism is so far unknown. Until recently, more attention are&#xD;
      focused on gene dysregulation hypothesis. The preliminary works of our laboratory prompted&#xD;
      that microRNA-30e gene polymorphism and expression abnormal may be related to schizophrenia.&#xD;
      Combined with previous studies showed that miRNA disorder involved in neurodevelopmental&#xD;
      obstacle and neuropsychiatric disease, the investigators surmised: miR-30e dysregulation can&#xD;
      impact the occurrence and development of schizophrenia. This study will carry on the&#xD;
      multidimensional research by using the technology of neurobiology, molecular&#xD;
      genetics,neuroimaging and so on, and integrate methods of molecular, cell, animal and human&#xD;
      body tracking, so as to:(1) Explaining the transcription and regulation mechanisms of target&#xD;
      genes of miR-30e,and building the gene regulatory network of schizophrenia as the core of&#xD;
      miR-30e.(2)To investigate the pathogenesis of miR-30e participate in schizophrenia, and to&#xD;
      evaluate the clinical value of miR-30e in peripheral blood on the disease diagnose,&#xD;
      genotyping, predicting efficacy and ending. The object of this study is to provide new&#xD;
      scientific data and research ideas for further exploring the neurobiological basis of&#xD;
      schizophrenia, and recognize pathophysiological mechanisms of schizophrenia, ultimately to&#xD;
      improve and strengthen the new situation in schizophrenia prevention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of schizophrenics with antipsychptic treatment who achieved remission assessed by PANSS.</measure>
    <time_frame>Number of schizophrenics with 12-week antipsychptic treatment who achieved remission assessed by PANSS.</time_frame>
    <description>The clinical effects were assessed by trained and experienced psychiatrists with the Positive and Negative Syndrome Scale (PANSS) before and after 12-week treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>antipsychotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group was treated with no invention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>a kind of antipsychotics</description>
    <arm_group_label>antipsychotics</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>a kind of antipsychotics</description>
    <arm_group_label>antipsychotics</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>a kind of antipsychotics</description>
    <arm_group_label>antipsychotics</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>a kind of antipsychotics</description>
    <arm_group_label>antipsychotics</arm_group_label>
    <other_name>Abilifya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>a kind of antipsychotics</description>
    <arm_group_label>antipsychotics</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unrelated Han Chinese recruited from the north of China.&#xD;
&#xD;
          -  Drug-free for at least one month before enrollment.&#xD;
&#xD;
          -  Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual&#xD;
             of Mental Disorders Fourth Edition (DSM-IV) criteria for SZ (American Psychiatric&#xD;
             Association, 1994), relying on the Chinese Version of the Modiﬁed Structured Clinical&#xD;
             Interview for DSM-IV TR Axis I Disorders Patient Edition (SCID-I/P,11/2002 revision).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or had signiﬁcant medical conditions.&#xD;
&#xD;
          -  Unstable psychiatric features (e.g., suicidal feelings).&#xD;
&#xD;
          -  A history of substance abuse or drug addiction within the previous 6 months, with the&#xD;
             exception of nicotine dependence.&#xD;
&#xD;
          -  Other Axis I co-morbid disorders were not excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Xu, Doctor</last_name>
    <phone>18234016125</phone>
    <email>xuyongsmu@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Clinical Medical College of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Xu, Doctor</last_name>
      <phone>18234016125</phone>
      <email>xuyongsmu@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Sha Liu, Doctor</last_name>
      <phone>15803400167</phone>
      <email>liusha1984114@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Yong Xu</investigator_full_name>
    <investigator_title>Dr Yong Xu</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

